{"id":10311,"date":"2026-09-15T07:16:40","date_gmt":"2026-09-15T12:16:40","guid":{"rendered":"https:\/\/nanostherapeutics.com\/?p=10311"},"modified":"2026-09-15T07:25:05","modified_gmt":"2026-09-15T12:25:05","slug":"nanoscope-therapeutics-to-present-long-term-mco-010-data-at-the-59th-annual-retina-society-meeting","status":"publish","type":"post","link":"https:\/\/nanostherapeutics.com\/ja\/2026\/09\/15\/nanoscope-therapeutics-to-present-long-term-mco-010-data-at-the-59th-annual-retina-society-meeting\/","title":{"rendered":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u793e\u3001\u7b2c59\u56de\u7db2\u819c\u5b66\u4f1a\u5e74\u6b21\u7dcf\u4f1a\u3067MCO-010\u306e\u9577\u671f\u30c7\u30fc\u30bf\u3092\u767a\u8868"},"content":{"rendered":"<div data-elementor-type=\"wp-post\" data-elementor-id=\"10311\" class=\"elementor elementor-10311\" data-elementor-post-type=\"post\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-6d5ad04f elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"6d5ad04f\" data-element_type=\"section\" data-e-type=\"section\">\r\n\t\t\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\r\n\t\t\t\t\r\n\t\t\t\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-5bf9bdef\" data-id=\"5bf9bdef\" data-element_type=\"column\" data-e-type=\"column\">\r\n\r\n\t\t\t\t\r\n\t\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\r\n\t\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-e3a8c93 elementor-widget-tablet__width-initial elementor-widget elementor-widget-text-editor\" data-id=\"e3a8c93\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<ul type=\"disc\"><li><i>Christine Kay, MD, to present 4-year long-term follow-up data from the RESTORE Phase 2b\/3 trial in retinitis pigmentosa patients<\/i><\/li><\/ul><p><span class=\"legendSpanClass\">\u30c0\u30e9\u30b9<\/span>,\u00a0<span class=\"legendSpanClass\">Sept. 15, 2026<\/span>\u00a0\u2014\u00a0<a href=\"http:\/\/nanostherapeutics.com\/ja\/\" target=\"_blank\" rel=\"nofollow noopener\">\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9<\/a>, Inc., a biotechnology company committed to developing and commercializing novel, disease-agnostic therapies for patients with photoreceptor loss and vision impairment due to retinal degeneration, today announced that Dr. Christine Kay, Director of Clinical Research and Retinal Genetics, Vitreoretinal Associates in\u00a0Gainesville,will present 4-year data from Nanoscope&#8217;s MCO-010 retinitis pigmentosa program at the\u00a0<a href=\"https:\/\/www.retinasociety.org\/page\/2\/annual-meeting\" target=\"_blank\" rel=\"nofollow noopener\"><b>59<\/b><b><sup>\u756a\u76ee<\/sup><\/b><b>\u00a0Annual Scientific Meeting of the Retina Society<\/b><\/a><b>, taking place September 23-26, 2026, in Los Angeles, California.<\/b><\/p><p><b>\u30d7\u30ec\u30bc\u30f3\u30c6\u30fc\u30b7\u30e7\u30f3\u306e\u8a73\u7d30\uff1a<\/b><\/p><p><b>\u30d7\u30ec\u30bc\u30f3\u30c6\u30fc\u30b7\u30e7\u30f3\u30bf\u30a4\u30c8\u30eb:\u00a0<\/b><i>Lasting Vision Improvement With MCO-010 Optogenetic Therapy: REMAIN 4-Year Study Data From the RESTORE Phase 2b\/3 Trial for Retinitis Pigmentosa<br \/><\/i><b>\u30d7\u30ec\u30bc\u30f3\u30bf\u30fc\uff1a\u00a0<\/b>\u30af\u30ea\u30b9\u30c6\u30a3\u30f3\u30fb\u30b1\u30a4\u533b\u5e2b<br \/><b>\u65e5\u6642\uff1a\u00a0<\/b>Wednesday, September 23, 2026, 3:15 PM PT<br \/><b>\u4f4d\u7f6e\uff1a\u00a0<\/b>Fairmont Century Plaza Hotel, Los Angeles, California<\/p><p>Dr. Kay will present expanded long-term durability of patient benefit in patients treated with MCO-010 (sonpiretigene isteparvovec, MOGENRY\u00ae). These data demonstrate that MOGENRY\u00ae-dosed patients continue to maintain visual acuity gains long after treatment. MOGENRY\u00ae is the only program to demonstrate sustained restoration of visual acuity with long-term durability, and the BLA for MOGENRY\u00ae<a href=\"https:\/\/nanostherapeutics.com\/ja\/2026\/09\/09\/nanoscope-therapeutics-announces-u-s-food-and-drug-administration-acceptance-of-biologics-license-application-for-mogenry-for-the-treatment-of-retinitis-pigmentosa-with-severe-vision-loss\/\" target=\"_blank\" rel=\"nofollow noopener\">\u00a0has been accepted and filed by the FDA<\/a>.<\/p><p><b>MOGENRY\u00ae\uff08\u30bd\u30f3\u30d4\u30ec\u30c1\u30b2\u30f3\u30fb\u30a4\u30b9\u30c6\u30d1\u30eb\u30dc\u30d9\u30c3\u30af\uff1bMCO-010\uff09\u306b\u3064\u3044\u3066<\/b><\/p><p>Nanoscope&#8217;s multi-characteristic opsin (MCO) technology utilizes a proprietary genetically engineered synthetic opsin to enable optimized performance in terms of high light sensitivity across a broad spectrum and fast kinetics. After Nanoscope&#8217;s Co-Founder, President, and Chief Scientific Officer, Samarendra Mohanty, envisioned and invented the technology, his team has spent over a decade evaluating its performance across multiple animal models and human diseases. MOGENRY\u00ae is an investigational, one-time, in-office, intravitreal optogenetic gene therapy built on Nanoscope&#8217;s MCO platform. By delivering a multi-characteristic opsin gene to the highly dense bipolar retinal cells, MOGENRY\u00ae makes these surviving cells directly light-sensitive, enabling them to utilize the remaining visual circuitry following photoreceptor loss. MOGENRY\u00ae does not require genetic testing, invasive surgery, or repeat dosing, and is designed for administration within existing retina office workflows.<\/p><p><b>\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u306b\u3064\u3044\u3066<\/b><\/p><p>\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u306f\u3001\u7db2\u819c\u5909\u6027\u75be\u60a3\u306b\u3088\u308a\u5931\u660e\u3057\u305f\u6570\u767e\u4e07\u4eba\u306e\u60a3\u8005\u306e\u305f\u3081\u306b\u3001\u75be\u60a3\u306e\u7a2e\u985e\u3092\u554f\u308f\u305a\u8996\u529b\u3092\u56de\u5fa9\u3055\u305b\u308b\u5149\u907a\u4f1d\u5b66\u7684\u6cbb\u7642\u6cd5\u3092\u958b\u767a\u3057\u3066\u3044\u307e\u3059\u3002\u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7\uff08RP\uff09\u3092\u5bfe\u8c61\u3068\u3057\u305f\u591a\u65bd\u8a2d\u5171\u540c\u7121\u4f5c\u70ba\u5316\u4e8c\u91cd\u76f2\u691c\u30d7\u30e9\u30bb\u30dc\u5bfe\u7167\u81e8\u5e8a\u8a66\u9a13\u3067\u3042\u308bRESTORE\u7b2c2b\/3\u76f8\u8a66\u9a13\u3067\u826f\u597d\u306a\u7d50\u679c\u304c\u5f97\u3089\u308c\u305f\u3053\u3068\u3092\u53d7\u3051\u3001<a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4773022-1&amp;h=610580003&amp;u=https%3A%2F%2Fprotect.checkpoint.com%2Fv2%2Fr01%2F___https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT04945772___.YXAzOm5hbm9zY29wZXRoZXJhcGV1dGljczpjOm9mZmljZTM2NV9lbWFpbHNfYXR0YWNobWVudDoyYzIwMjMwOGRmZmU0NDVlNzU1NDhhOTVlMDAzZTM1MTo3OmEyNmQ6NWRkNDk4NDJiOTMyYmNlYjczNDA1M2E3NDI0ODNiZTgwY2VhNmVmOWUyOGJjMjg3NzI3NzMzNTg4YmY2YWYzYjpwOlQ6Rg&amp;a=NCT04945772\" target=\"_blank\" rel=\"nofollow noopener\">NCT04945772<\/a>), the\u00a0<a href=\"https:\/\/nanostherapeutics.com\/ja\/2026\/09\/09\/nanoscope-therapeutics-announces-u-s-food-and-drug-administration-acceptance-of-biologics-license-application-for-mogenry-for-the-treatment-of-retinitis-pigmentosa-with-severe-vision-loss\/\" target=\"_blank\" rel=\"nofollow noopener\">FDA has accepted and filed the Company&#8217;s BLA for MOGENRY\u00ae<\/a>. If approved, MOGENRY\u00ae has the potential to become the standard of care for patients with RP, administered as a one-time, in-office injection without the need for genetic testing. The Company has also shown promising results in the STARLIGHT Phase 2 clinical trial of MCO-010 in Stargardt disease (SD) (<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT05417126\" target=\"_blank\" rel=\"nofollow noopener\">NCT05417126<\/a>\uff09\u3067\u3042\u308a\u30012026\u5e74\u306b\u7b2c3\u76f8\u767b\u9332\u8a66\u9a13\u3092\u958b\u59cb\u3059\u308b\u4e88\u5b9a\u3067\u3059\u3002MCO-010\u306f\u3001RP\u3068SD\u306e\u4e21\u65b9\u3067FDA\u306e\u30d5\u30a1\u30b9\u30c8\u30c8\u30e9\u30c3\u30af\u304a\u3088\u3073\u30aa\u30fc\u30d5\u30a1\u30f3\u30c9\u30e9\u30c3\u30b0\u6307\u5b9a\u3092\u53d7\u3051\u3066\u304a\u308a\u3001SD\u306b\u3064\u3044\u3066\u306fRMAT\u6307\u5b9a\u3082\u53d7\u3051\u3066\u3044\u307e\u3059\u3002\u307e\u305f\u3001\u975e\u75c7\u5019\u6027\u304a\u3088\u3073\u75c7\u5019\u6027\u306e\u687f\u4f53\u304a\u3088\u3073\u9310\u4f53\u512a\u4f4d\u6027\u30b8\u30b9\u30c8\u30ed\u30d5\u30a3\u30fc\u3001\u306a\u3089\u3073\u306b\u9ec4\u6591\u30b8\u30b9\u30c8\u30ed\u30d5\u30a3\u30fc\u3092\u5bfe\u8c61\u3068\u3057\u305fEMA\u306e\u30aa\u30fc\u30d5\u30a1\u30f3\u6307\u5b9a\u3082\u53d7\u3051\u3066\u3044\u307e\u3059\u3002MCO-010\u306f\u3001\u65e5\u672c\u3067\u306f\u907a\u4f1d\u6027\u7db2\u819c\u30b8\u30b9\u30c8\u30ed\u30d5\u30a3\u30fc\uff08IRD\uff09\u306e\u5148\u99c6\u3051\u6307\u5b9a\u304a\u3088\u3073\u30aa\u30fc\u30d5\u30a1\u30f3\u6307\u5b9a\u3092\u53d7\u3051\u3066\u304a\u308a\u3001\u30b5\u30a6\u30b8\u30a2\u30e9\u30d3\u30a2\u3067\u306fIRD\u306e\u30aa\u30fc\u30d5\u30a1\u30f3\u6307\u5b9a\u3092\u53d7\u3051\u3066\u3044\u307e\u3059\u3002\u5730\u7406\u7684\u840e\u7e2e\u75c7\u306b\u5bfe\u3059\u308bMCO\u306e\u7b2c2\u76f8\u30d7\u30ed\u30b0\u30e9\u30e0\u306f2026\u5e74\u306b\u958b\u59cb\u3055\u308c\u308b\u4e88\u5b9a\u3067\u3042\u308a\u3001IND\u6e96\u5099\u4e2d\u306e\u4ed6\u306e\u30d7\u30ed\u30b0\u30e9\u30e0\u306b\u306f\u30ec\u30fc\u30d0\u30fc\u5148\u5929\u6027\u9ed2\u5185\u969c\uff08LCA\uff09\u304c\u542b\u307e\u308c\u307e\u3059\u3002.<\/p><p><b>\u63a5\u89e6\uff1a<\/b><\/p><p>\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u793e<br class=\"dnr\" \/>(817) 857-1186<br class=\"dnr\" \/><u><a href=\"mailto:PR@nanostherapeutics.com\" target=\"_blank\" rel=\"nofollow noopener\">PR@nanostherapeutics.com<\/a><\/u><\/p><p>\u51fa\u5178 \u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9<\/p><p><img decoding=\"async\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=DA46696&amp;Transmission_Id=202609150702PR_NEWS_USPR_____DA46696&amp;DateId=20260915\" alt=\"\" \/><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\r\n\t\t\t\t<\/div>\r\n\t\t\t\t\t\t\t\t<\/div>\r\n\t\t\t<\/section>\r\n\t\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"<p>Christine Kay, MD, to present 4-year long-term follow-up data from the RESTORE Phase 2b\/3 trial in retinitis pigmentosa patients DALLAS,\u00a0Sept. 15, 2026\u00a0&#8212;\u00a0Nanoscope Therapeutics, Inc., a biotechnology company committed to developing and commercializing novel, disease-agnostic therapies for patients with photoreceptor loss and vision impairment due to retinal degeneration, today announced that Dr. Christine Kay, Director of Clinical Research and Retinal Genetics, Vitreoretinal Associates in\u00a0Gainesville,will present 4-year data from Nanoscope&#8217;s MCO-010 retinitis pigmentosa program at the\u00a059th\u00a0Annual Scientific Meeting of the Retina Society, taking place September 23-26, 2026, in Los Angeles, California. Presentation Details: Presentation Title:\u00a0Lasting Vision Improvement With MCO-010 Optogenetic Therapy: REMAIN 4-Year Study Data From the RESTORE Phase 2b\/3 Trial for [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":10313,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[13,8],"tags":[],"class_list":["post-10311","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-home-page","category-nanoscope-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nanoscope Therapeutics to Present Long-Term MCO-010 Data at the 59th Annual Retina Society Meeting - Nanoscope Therapeutics<\/title>\n<meta name=\"description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanostherapeutics.com\/ja\/2026\/09\/15\/nanoscope-therapeutics-to-present-long-term-mco-010-data-at-the-59th-annual-retina-society-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"ja_JP\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanoscope Therapeutics to Present Long-Term MCO-010 Data at the 59th Annual Retina Society Meeting - Nanoscope Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanostherapeutics.com\/ja\/2026\/09\/15\/nanoscope-therapeutics-to-present-long-term-mco-010-data-at-the-59th-annual-retina-society-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanoscope Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-15T12:16:40+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-15T12:25:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"242\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Wilson PJ\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:site\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:label1\" content=\"\u57f7\u7b46\u8005\" \/>\n\t<meta name=\"twitter:data1\" content=\"Wilson PJ\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593\" \/>\n\t<meta name=\"twitter:data2\" content=\"3\u5206\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/09\\\/15\\\/nanoscope-therapeutics-to-present-long-term-mco-010-data-at-the-59th-annual-retina-society-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/09\\\/15\\\/nanoscope-therapeutics-to-present-long-term-mco-010-data-at-the-59th-annual-retina-society-meeting\\\/\"},\"author\":{\"name\":\"Wilson PJ\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/2fa4c7d9fcf90c2c01f1341935baf02d\"},\"headline\":\"Nanoscope Therapeutics to Present Long-Term MCO-010 Data at the 59th Annual Retina Society Meeting\",\"datePublished\":\"2026-09-15T12:16:40+00:00\",\"dateModified\":\"2026-09-15T12:25:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/09\\\/15\\\/nanoscope-therapeutics-to-present-long-term-mco-010-data-at-the-59th-annual-retina-society-meeting\\\/\"},\"wordCount\":550,\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/09\\\/15\\\/nanoscope-therapeutics-to-present-long-term-mco-010-data-at-the-59th-annual-retina-society-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_LI_MIDDLE_2025.jpg\",\"articleSection\":[\"Home Page\",\"Nanoscope Press Release\"],\"inLanguage\":\"ja\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/09\\\/15\\\/nanoscope-therapeutics-to-present-long-term-mco-010-data-at-the-59th-annual-retina-society-meeting\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/09\\\/15\\\/nanoscope-therapeutics-to-present-long-term-mco-010-data-at-the-59th-annual-retina-society-meeting\\\/\",\"name\":\"Nanoscope Therapeutics to Present Long-Term MCO-010 Data at the 59th Annual Retina Society Meeting - Nanoscope Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/09\\\/15\\\/nanoscope-therapeutics-to-present-long-term-mco-010-data-at-the-59th-annual-retina-society-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/09\\\/15\\\/nanoscope-therapeutics-to-present-long-term-mco-010-data-at-the-59th-annual-retina-society-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_LI_MIDDLE_2025.jpg\",\"datePublished\":\"2026-09-15T12:16:40+00:00\",\"dateModified\":\"2026-09-15T12:25:05+00:00\",\"description\":\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/09\\\/15\\\/nanoscope-therapeutics-to-present-long-term-mco-010-data-at-the-59th-annual-retina-society-meeting\\\/#breadcrumb\"},\"inLanguage\":\"ja\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/09\\\/15\\\/nanoscope-therapeutics-to-present-long-term-mco-010-data-at-the-59th-annual-retina-society-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ja\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/09\\\/15\\\/nanoscope-therapeutics-to-present-long-term-mco-010-data-at-the-59th-annual-retina-society-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_LI_MIDDLE_2025.jpg\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_LI_MIDDLE_2025.jpg\",\"width\":1200,\"height\":800},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/09\\\/15\\\/nanoscope-therapeutics-to-present-long-term-mco-010-data-at-the-59th-annual-retina-society-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nanostherapeutics.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanoscope Therapeutics to Present Long-Term MCO-010 Data at the 59th Annual Retina Society Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"name\":\"Nanoscope Therapeutics\",\"description\":\"Bringing Back the Light of Hope\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"alternateName\":\"Nanoscope Therapeutics\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanostherapeutics.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ja\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\",\"name\":\"Nanoscope Therapeutics, Inc\",\"alternateName\":\"Nanoscope Therapeutics\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ja\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"width\":512,\"height\":435,\"caption\":\"Nanoscope Therapeutics, Inc\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/NSTherapeutics\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/nanoscope\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/2fa4c7d9fcf90c2c01f1341935baf02d\",\"name\":\"Wilson PJ\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanoscope Therapeutics to Present Long-Term MCO-010 Data at the 59th Annual Retina Society Meeting - Nanoscope Therapeutics","description":"\u5f53\u793e\u306e\u591a\u6a5f\u80fd\u30aa\u30d7\u30b7\u30f3\uff08MCO\uff09\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u306f\u3001\u81e8\u5e8a\u8a66\u9a13\u306b\u304a\u3044\u3066\u91cd\u5ea6\u306e\u8996\u529b\u55aa\u5931\u3092\u4f34\u3046\u7db2\u819c\u75be\u60a3\u60a3\u8005\u306e\u8996\u529b\u3092\u56de\u5fa9\u3055\u305b\u308b\u80fd\u529b\u3092\u5b9f\u8a3c\u3057\u305f\u521d\u306e\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u3067\u3059\u3002Nanoscope\u793e\u306f\u3001\u907a\u4f1d\u5b50\u306b\u4f9d\u5b58\u3057\u306a\u3044\u3001\u5e83\u7bc4\u56f2\u306e\u30b9\u30da\u30af\u30c8\u30eb\u3001\u9ad8\u901f\u5fdc\u7b54\u6027\u3001\u8d85\u9ad8\u611f\u5ea6\u3092\u5099\u3048\u305f\u3001\u8996\u529b\u56de\u5fa9\u306e\u305f\u3081\u306e\u6700\u521d\u3067\u552f\u4e00\u306e\u5149\u907a\u4f1d\u5b66\u6280\u8853\u3067\u3042\u308bMCO-010\u3092\u958b\u767a\u3057\u307e\u3057\u305f\u3002.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanostherapeutics.com\/ja\/2026\/09\/15\/nanoscope-therapeutics-to-present-long-term-mco-010-data-at-the-59th-annual-retina-society-meeting\/","og_locale":"ja_JP","og_type":"article","og_title":"Nanoscope Therapeutics to Present Long-Term MCO-010 Data at the 59th Annual Retina Society Meeting - Nanoscope Therapeutics","og_description":"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.","og_url":"https:\/\/nanostherapeutics.com\/ja\/2026\/09\/15\/nanoscope-therapeutics-to-present-long-term-mco-010-data-at-the-59th-annual-retina-society-meeting\/","og_site_name":"Nanoscope Therapeutics","article_published_time":"2026-09-15T12:16:40+00:00","article_modified_time":"2026-09-15T12:25:05+00:00","og_image":[{"width":1200,"height":242,"url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg","type":"image\/jpeg"}],"author":"Wilson PJ","twitter_card":"summary_large_image","twitter_creator":"@NSTherapeutics","twitter_site":"@NSTherapeutics","twitter_misc":{"\u57f7\u7b46\u8005":"Wilson PJ","\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593":"3\u5206"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nanostherapeutics.com\/2026\/09\/15\/nanoscope-therapeutics-to-present-long-term-mco-010-data-at-the-59th-annual-retina-society-meeting\/#article","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/2026\/09\/15\/nanoscope-therapeutics-to-present-long-term-mco-010-data-at-the-59th-annual-retina-society-meeting\/"},"author":{"name":"Wilson PJ","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/2fa4c7d9fcf90c2c01f1341935baf02d"},"headline":"Nanoscope Therapeutics to Present Long-Term MCO-010 Data at the 59th Annual Retina Society Meeting","datePublished":"2026-09-15T12:16:40+00:00","dateModified":"2026-09-15T12:25:05+00:00","mainEntityOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2026\/09\/15\/nanoscope-therapeutics-to-present-long-term-mco-010-data-at-the-59th-annual-retina-society-meeting\/"},"wordCount":550,"publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2026\/09\/15\/nanoscope-therapeutics-to-present-long-term-mco-010-data-at-the-59th-annual-retina-society-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_LI_MIDDLE_2025.jpg","articleSection":["Home Page","Nanoscope Press Release"],"inLanguage":"ja"},{"@type":"WebPage","@id":"https:\/\/nanostherapeutics.com\/2026\/09\/15\/nanoscope-therapeutics-to-present-long-term-mco-010-data-at-the-59th-annual-retina-society-meeting\/","url":"https:\/\/nanostherapeutics.com\/2026\/09\/15\/nanoscope-therapeutics-to-present-long-term-mco-010-data-at-the-59th-annual-retina-society-meeting\/","name":"Nanoscope Therapeutics to Present Long-Term MCO-010 Data at the 59th Annual Retina Society Meeting - Nanoscope Therapeutics","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2026\/09\/15\/nanoscope-therapeutics-to-present-long-term-mco-010-data-at-the-59th-annual-retina-society-meeting\/#primaryimage"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2026\/09\/15\/nanoscope-therapeutics-to-present-long-term-mco-010-data-at-the-59th-annual-retina-society-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_LI_MIDDLE_2025.jpg","datePublished":"2026-09-15T12:16:40+00:00","dateModified":"2026-09-15T12:25:05+00:00","description":"\u5f53\u793e\u306e\u591a\u6a5f\u80fd\u30aa\u30d7\u30b7\u30f3\uff08MCO\uff09\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u306f\u3001\u81e8\u5e8a\u8a66\u9a13\u306b\u304a\u3044\u3066\u91cd\u5ea6\u306e\u8996\u529b\u55aa\u5931\u3092\u4f34\u3046\u7db2\u819c\u75be\u60a3\u60a3\u8005\u306e\u8996\u529b\u3092\u56de\u5fa9\u3055\u305b\u308b\u80fd\u529b\u3092\u5b9f\u8a3c\u3057\u305f\u521d\u306e\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u3067\u3059\u3002Nanoscope\u793e\u306f\u3001\u907a\u4f1d\u5b50\u306b\u4f9d\u5b58\u3057\u306a\u3044\u3001\u5e83\u7bc4\u56f2\u306e\u30b9\u30da\u30af\u30c8\u30eb\u3001\u9ad8\u901f\u5fdc\u7b54\u6027\u3001\u8d85\u9ad8\u611f\u5ea6\u3092\u5099\u3048\u305f\u3001\u8996\u529b\u56de\u5fa9\u306e\u305f\u3081\u306e\u6700\u521d\u3067\u552f\u4e00\u306e\u5149\u907a\u4f1d\u5b66\u6280\u8853\u3067\u3042\u308bMCO-010\u3092\u958b\u767a\u3057\u307e\u3057\u305f\u3002.","breadcrumb":{"@id":"https:\/\/nanostherapeutics.com\/2026\/09\/15\/nanoscope-therapeutics-to-present-long-term-mco-010-data-at-the-59th-annual-retina-society-meeting\/#breadcrumb"},"inLanguage":"ja","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanostherapeutics.com\/2026\/09\/15\/nanoscope-therapeutics-to-present-long-term-mco-010-data-at-the-59th-annual-retina-society-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/nanostherapeutics.com\/2026\/09\/15\/nanoscope-therapeutics-to-present-long-term-mco-010-data-at-the-59th-annual-retina-society-meeting\/#primaryimage","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_LI_MIDDLE_2025.jpg","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_LI_MIDDLE_2025.jpg","width":1200,"height":800},{"@type":"BreadcrumbList","@id":"https:\/\/nanostherapeutics.com\/2026\/09\/15\/nanoscope-therapeutics-to-present-long-term-mco-010-data-at-the-59th-annual-retina-society-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nanostherapeutics.com\/"},{"@type":"ListItem","position":2,"name":"Nanoscope Therapeutics to Present Long-Term MCO-010 Data at the 59th Annual Retina Society Meeting"}]},{"@type":"WebSite","@id":"https:\/\/nanostherapeutics.com\/#website","url":"https:\/\/nanostherapeutics.com\/","name":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9","description":"\u5e0c\u671b\u306e\u5149\u3092\u53d6\u308a\u623b\u3059","publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"alternateName":"Nanoscope Therapeutics","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanostherapeutics.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ja"},{"@type":"Organization","@id":"https:\/\/nanostherapeutics.com\/#organization","name":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u793e","alternateName":"Nanoscope Therapeutics","url":"https:\/\/nanostherapeutics.com\/","logo":{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","width":512,"height":435,"caption":"Nanoscope Therapeutics, Inc"},"image":{"@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/NSTherapeutics","https:\/\/www.linkedin.com\/company\/nanoscope"]},{"@type":"Person","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/2fa4c7d9fcf90c2c01f1341935baf02d","name":"\u30a6\u30a3\u30eb\u30bd\u30f3 PJ"}]}},"_links":{"self":[{"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/posts\/10311","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/comments?post=10311"}],"version-history":[{"count":6,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/posts\/10311\/revisions"}],"predecessor-version":[{"id":10319,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/posts\/10311\/revisions\/10319"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/media\/10313"}],"wp:attachment":[{"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/media?parent=10311"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/categories?post=10311"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/tags?post=10311"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}